MET and non-small cell lung carcinoma: In EGFR‐TKIS‐resistant NSCLC cells, the PI3K/AKT and MAPK signaling pathways are involved in the upregulation of PD‐L1 induced by c‐MET amplification; EGFR‐T790M mutation upregulated PD‐L1 expression through the PI3K/AKT MAPK and NF‐kappa B (Nuclear factor kappa‐B, NF‐κB) signaling pathways.